Abstract:Reversible protein phosphorylation directs essential cellular processes including cell division, cell growth, cell death, inflammation, and differentiation. Because protein phosphorylation drives diverse diseases, kinases and phosphatases have been targets for drug discovery, with some achieving remarkable clinical success. Most protein kinases are activated by phosphorylation of their activation loops, which shifts the conformational equilibrium of the kinase towards the active state. To turn off the kinase, protein phosphatases dephosphorylate these sites, but how the conformation of the dynamic activation loop contributes to dephosphorylation was not known. To answer this, we modulated the activation loop conformational equilibrium of human p38α ΜΑP kinase with existing kinase inhibitors that bind and stabilize specific inactive activation loop conformations. From this, we discovered three inhibitors that increase the rate of dephosphorylation of the activation loop phospho-threonine by the PPM serine/threonine phosphatase WIP1. Hence, these compounds are "dual-action" inhibitors that simultaneously block the active site and stimulate p38α dephosphorylation. Our X-ray crystal structures of phosphorylated p38α bound to the dual-action inhibitors reveal a shared flipped conformation of the activation loop with a fully accessible phospho-threonine. In contrast, our X-ray crystal structure of phosphorylated apo human p38α reveals a different activation loop conformation with an inaccessible phospho-threonine, thereby explaining the increased rate of dephosphorylation upon inhibitor binding. These findings reveal a conformational preference of phosphatases for their targets and suggest a new approach to achieving improved potency and specificity for therapeutic kinase inhibitors.

Dual-Action Kinase Inhibitors Influence p38α MAP Kinase Dephosphorylation

Dual-Action Kinase Inhibitors Control p38α MAP Kinase Threonine Dephosphorylation

Structural Insights into the Enzymatic Mechanism of the Pathogenic MAPK Phosphothreonine Lyase.

Enzymatic Activity and Substrate Specificity of Mitogen-activated Protein Kinase p38α in Different Phosphorylation States

Molecular Dynamics Simulation and Free Energy Calculation Studies of the Binding Mechanism of Allosteric Inhibitors with P38α MAP Kinase.

Enzymatic activity and substrate specificity of mitogen-activated protein kinase p38alpha in different phosphorylation states

TAB1 Binding Induced P38α Conformation Change: an Accelerated Molecular Dynamics Simulation Study.

A distinct interaction mode revealed by the crystal structure of the kinase p38α with the MAPK binding domain of the phosphatase MKP5.

Kinetic and mechanistic studies of p38α MAP kinase phosphorylation by MKK6.

Targeting inactive enzyme conformation: aryl diketoacid derivatives as a new class of PTP1B inhibitors.

Structure-Based Discovery of Small Molecule Inhibitors Targeted to Protein Tyrosine Phosphatase 1B

Novel Strategies for Inhibition of the P38 MAPK Pathway.

Phosphatidylinositol Ether Lipid Analogues That Inhibit AKT Also Independently Activate the Stress Kinase, p38α, through MKK3/6-independent and -dependent Mechanisms

Structure-Function Studies of p38 Mitogen-activated Protein Kinase: LOOP 12 INFLUENCES SUBSTRATE SPECIFICITY AND AUTOPHOSPHORYLATION, BUT NOT UPSTREAM KINASE SELECTION

Investigation of Selective Binding of Inhibitors to PTP1B and TCPTP by Accelerated Molecular Dynamics Simulations.

Inhibition of Hematopoietic Protein Tyrosine Phosphatase Augments and Prolongs ERK1/2 and P38 Activation

Revealing the Favorable Dissociation Pathway of Type II Kinase Inhibitors Via Enhanced Sampling Simulations and Two-End-state Calculations

Dual Roles of ATP-binding Site in Protein Kinases: Orthosteric Inhibition and Allosteric Regulation.

Binding Mechanism of Inhibitors to P38α MAP Kinase Deciphered by Using Multiple Replica Gaussian Accelerated Molecular Dynamics and Calculations of Binding Free Energies.

P38 Mitogen‐activated Protein Kinase: Functions and Targeted Therapy in Diseases

Ligand-based 3D pharmacophore design, virtual screening and molecular docking for novel p38 MAPK inhibitors